By. Dr's. Jamal Gasmi, James Conklin and Gregory Goldmacher. The pharmaceutical industry’s R&D productivity is hampered by the reality behind one disheartening statistic: over 40 percent of all therapeutic agents deemed successful in Phase II programs subsequently fail in Phase III studies. Given the cost of Phase III trials, companies pay a staggering price for their inability to identify unsuccessful candidates prior to late-stage development.
International Women’s Week: Dr Anuradha Rajput, MD, ICON Central Laboratories, India, speaks about how one needs to have a work-life balance to be happy
By Tom McCloskey, Carla Hill, Chengsen Xue of ICON Development of new anti-tumor drugs is time consuming and costly. Is there an effective pharmacodynamic biomarker able to predict early success or failure of a drug candidate in development?
Contract Pharma - Integrated methodologies for early assessment. By Cyril Clarke, ICON.
Outsourcing is a growing trend in the pharmaceutical industry. Demands for central laboratory testing using complex cell-based assays throughout all phases of drug development are on the rise.
Dr Anuradha Rajput, managing director, ICON Central Laboratories, India, speaks about her scientific journey and how her science-oriented aptitude has helped spearhead Icon into becoming a prominent CRO in India
Contract Pharma magazine November 2012 - Dr. Gregory V. Goldmacher of ICON Medical Imaging reviews recent suggestions by the FDA Oncologic Drugs Advisory Committee (ODAC) for the interpretation of radiological images from clinical trials that target solid tumors, and for which progression-free survival (PFS) is a key endpoint.
In recent years, the use of imaging in the pre-clinical stages of drug development has exploded, perhaps most markedly in Asia Pacific region. Valerie Treyer talks about the role of Imaging biomarkers in early-phase development.
PharmaVoice, June 2012. Contributed by Adrian Levy, PH.D., Senior Scientific Advisor, Oxford Outcomes, an ICON plc company and Nigel Gregson, Partner, PriceSpective an ICON plc company